Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent

• Autors principals: Zongru Jiang (Autor), Li Wang (Autor), Xuesong Liu (Autor), Cheng Chen (Autor), Beilei Wang (Autor), Wenliang Wang (Autor), Chen Hu (Autor), Kailin Yu (Autor), Ziping Qi (Autor), Qingwang Liu (Autor), Aoli Wang (Autor), Jing Liu (Autor), Guangchen Hong (Autor), Wenchao Wang (Autor), Qingsong Liu (Autor)
• Format: Llibre
• Publicat: Elsevier, 2020-03-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Angiogenesis is an essential process in tumor growth, invasion and metastasis. VEGF receptor 2 (VEGFR2) inhibitors targeting tumor angiogenic pathway have been widely used in the clinical cancer treatment. However, most of currently used VEGFR2 kinase inhibitors are multi-target inhibitors which mig...